• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尼非卡兰与胺碘酮治疗院外心搏骤停患者电击除颤后顽固室颤的对比研究。

Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients.

机构信息

Department of Cardiology, Tokai University School of Medicine, Isehara, Japan.

出版信息

J Cardiovasc Pharmacol. 2010 Apr;55(4):391-8. doi: 10.1097/FJC.0b013e3181d3dcc7.

DOI:10.1097/FJC.0b013e3181d3dcc7
PMID:20147846
Abstract

BACKGROUND

In Japan, intravenous nifekalant (NIF) was often used for direct current cardioversion-resistant ventricular fibrillation (VF), until the use of intravenous amiodarone (AMD) was approved in 2007. The defibrillatory efficacy of NIF and AMD has thus far not been compared for resuscitation.

METHODS AND RESULTS

Between August 2007 and April 2009, 403 consecutive out-of-hospital patients with cardiopulmonary arrest were transferred to the Emergency Medical Service of Tokai University. Of these, 30 patients with first defibrillation failure or VF recurrence were enrolled for this NIF/AMD study. The final defibrillation success (and hospital survival rate) was 67% (10/15) in the AMD and 47% (7/15) in the NIF group. The discharge survival rate was 53% (8/15) in the AMD and 21% (4/15) in the NIF group (P = 0.06). Notably, all 4 survivors in the NIF group could take up normal daily life again, whereas this was restricted to only 2 patients from the 11 survivors in the AMD group. The difference is probably partly attributable to longer time from AMD administration to defibrillation success compared with NIF. In the cases of defibrillation failure, VF continued in 4/8 by NIF, however, asystole or pulseless electrical activity occurred in 4/5 patients by AMD.

CONCLUSIONS

AMD may be borderline superior over NIF to facilitate defibrillation in out-of-hospital patients with cardiopulmonary arrest. However, from the view point of preservation of brain function, NIF is not inferior to AMD for CPR.

摘要

背景

在日本,静脉注射尼非卡兰(NIF)常被用于直流电转复无效的心室颤动(VF),直到 2007 年批准使用静脉注射胺碘酮(AMD)。到目前为止,还没有比较过 NIF 和 AMD 在复苏中的除颤效果。

方法和结果

2007 年 8 月至 2009 年 4 月,403 例院外心肺骤停患者被转至东海大学急救医疗服务中心。其中,30 例首次除颤失败或 VF 复发的患者被纳入本项 NIF/AMD 研究。AMD 组的最终除颤成功(和出院存活率)为 67%(10/15),NIF 组为 47%(7/15)。AMD 组的出院存活率为 53%(8/15),NIF 组为 21%(4/15)(P = 0.06)。值得注意的是,NIF 组的所有 4 例存活患者都能恢复正常的日常生活,而 AMD 组的 11 例存活患者中只有 2 例能做到这一点。这种差异可能部分归因于与 NIF 相比,AMD 给药至除颤成功的时间更长。在除颤失败的情况下,NIF 使 4/8 例继续发生 VF,而 AMD 使 4/5 例发生停搏或无脉电活动。

结论

AMD 可能在一定程度上优于 NIF,有助于院外心肺骤停患者除颤。然而,从脑功能保护的角度来看,NIF 并不逊于 AMD 用于 CPR。

相似文献

1
Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients.尼非卡兰与胺碘酮治疗院外心搏骤停患者电击除颤后顽固室颤的对比研究。
J Cardiovasc Pharmacol. 2010 Apr;55(4):391-8. doi: 10.1097/FJC.0b013e3181d3dcc7.
2
[Efficacy of Nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest].盐酸尼非卡兰对利多卡因耐药的危及生命的室性快速心律失常患者的疗效:院外心脏骤停患者的研究
J Cardiol. 2003 Mar;41(3):127-34.
3
Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation.胺碘酮用于院外心室颤动心脏骤停后的复苏。
N Engl J Med. 1999 Sep 16;341(12):871-8. doi: 10.1056/NEJM199909163411203.
4
Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia.尼非卡兰与利多卡因治疗院内抗休克性室颤或室速。
Resuscitation. 2010 Jan;81(1):47-52. doi: 10.1016/j.resuscitation.2009.09.027. Epub 2009 Nov 13.
5
Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest.比较尼非卡兰和胺碘酮在猪心搏骤停模型中的疗效。
Resuscitation. 2010 Aug;81(8):1031-6. doi: 10.1016/j.resuscitation.2010.04.023. Epub 2010 Jun 2.
6
Pediatric defibrillation doses often fail to terminate prolonged out-of-hospital ventricular fibrillation in children.儿科除颤剂量往往无法终止儿童长时间的院外心室颤动。
Resuscitation. 2005 Oct;67(1):63-7. doi: 10.1016/j.resuscitation.2005.04.018.
7
Nifekalant Hydrochloride and Amiodarone Hydrochloride Result in Similar Improvements for 24-Hour Survival in Cardiopulmonary Arrest Patients: The SOS-KANTO 2012 Study.盐酸尼非卡兰与盐酸胺碘酮对心脏骤停患者24小时生存率的改善效果相似:SOS-KANTO 2012研究
J Cardiovasc Pharmacol. 2015 Dec;66(6):600-9. doi: 10.1097/FJC.0000000000000310.
8
Long-term subjective memory function in ventricular fibrillation out-of-hospital cardiac arrest survivors resuscitated by early defibrillation.早期除颤复苏的院外心脏骤停心室颤动幸存者的长期主观记忆功能。
Resuscitation. 2004 Feb;60(2):189-95. doi: 10.1016/j.resuscitation.2003.09.010.
9
Shortening of cardiopulmonary resuscitation time before the defibrillation worsens the outcome in out-of-hospital VF patients.在对院外室颤患者进行除颤之前缩短心肺复苏时间会使预后恶化。
Am J Emerg Med. 2009 May;27(4):470-4. doi: 10.1016/j.ajem.2008.03.043.
10
Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation.尼非卡兰与胺碘酮治疗心脏骤停:在猪长时间室颤模型中的实验研究
Cardiovasc Drugs Ther. 2015;29(5):425-31. doi: 10.1007/s10557-015-6604-7.

引用本文的文献

1
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.《日本循环学会/日本心律学会2020年心律失常药物治疗指南》
J Arrhythm. 2022 Oct 25;38(6):833-973. doi: 10.1002/joa3.12714. eCollection 2022 Dec.
2
Comparing Drugs for Out-of-hospital, Shock-refractory Cardiac Arrest: Systematic Review and Network Meta-analysis of Randomized Controlled Trials.比较院外、休克难治性心脏骤停的药物治疗:随机对照试验的系统评价和网络荟萃分析。
West J Emerg Med. 2021 Jul 19;22(4):834-841. doi: 10.5811/westjem.2021.2.49590.
3
Anesthetic management of a patient with severe aortic regurgitation undergoing reoperation for ascending aorta false aneurysm using hypothermia: prevention of ventricular fibrillation by nifekalant.
一名重度主动脉瓣反流患者在接受升主动脉假性动脉瘤再次手术时采用低温麻醉管理:使用尼非卡兰预防心室颤动。
JA Clin Rep. 2021 May 20;7(1):43. doi: 10.1186/s40981-021-00446-8.
4
Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia.胺碘酮与尼非卡兰治疗电击复律失败的室颤和无脉性室速的疗效的 Meta 分析。
Sci Rep. 2017 Oct 4;7(1):12683. doi: 10.1038/s41598-017-13073-0.
5
Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation.抗心律失常药物治疗院外心搏骤停伴顽固性心室颤动。
Crit Care. 2017 Mar 21;21(1):59. doi: 10.1186/s13054-017-1639-8.
6
A multicenter observational study of the effectiveness of antiarrhythmic agents in ventricular arrhythmias: A propensity-score adjusted analysis.抗心律失常药物治疗室性心律失常有效性的多中心观察性研究:倾向评分调整分析
J Arrhythm. 2016 Jun;32(3):186-90. doi: 10.1016/j.joa.2016.01.004. Epub 2016 Feb 10.
7
Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation.尼非卡兰与胺碘酮用于抢救因抗休克室颤导致的院外心脏骤停的比较。
J Anesth. 2014 Aug;28(4):587-92. doi: 10.1007/s00540-013-1775-5. Epub 2014 Jan 5.
8
Antiarrhythmia drugs for cardiac arrest: a systemic review and meta-analysis.用于心脏骤停的抗心律失常药物:一项系统评价和荟萃分析。
Crit Care. 2013 Aug 12;17(4):R173. doi: 10.1186/cc12852.
9
Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias.尼非卡兰治疗危及生命的室性快速心律失常。
World J Cardiol. 2011 Jun 26;3(6):169-76. doi: 10.4330/wjc.v3.i6.169.